Imricor Medical Systems (ASX: IMR) has announced that Swissmedic has approved the VISABL-AFL clinical trial to commence at the Lausanne University Hospital (CHUV) in Switzerland.
Swissmedic's approval is the final required for CHUV to join the trial. CHUV's ethics committee has approved the study. Imricor said installation planning has begun, and cases are expected to commence in the present quarter.
Imricor chair and CEO Steve Wedan said, “This is another major milestone in our execution of VISABL-AFL clinical trial and in the opening of the US market for Imricor. This marks the third site fully approved to commence the trial, and we are nearing the phase where patients are enrolled and treated. We are right on track with our plans and schedules.”
Imricor is developing innovative MRI-compatible medical devices that can be used to carry out real-time iCMR cardiac ablation procedures.